Monopar Therapeutics (NASDAQ:MNPR) CEO Sells $2,556,928.00 in Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) CEO Chandler Robinson sold 29,056 shares of the firm’s stock in a transaction on Thursday, September 24th. The stock was sold at an average price of $88.00, for a total value of $2,556,928.00. Following the transaction, the chief executive officer owned 99,267 shares of the company’s stock, valued at approximately $8,735,496. This represents a 22.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Price Performance

MNPR opened at $79.67 on Thursday. Monopar Therapeutics Inc. has a 12 month low of $50.07 and a 12 month high of $124.82. The stock has a market capitalization of $534.59 million, a price-to-earnings ratio of -36.71 and a beta of 1.49. The business has a fifty day moving average price of $108.44 and a 200 day moving average price of $82.64.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.02. On average, research analysts anticipate that Monopar Therapeutics Inc. will post -2.98 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on MNPR shares. Wall Street Zen raised Monopar Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. UBS Group set a $125.00 price target on shares of Monopar Therapeutics in a report on Thursday, July 23rd. BTIG Research upped their target price on Monopar Therapeutics from $117.00 to $133.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Morgan Stanley reaffirmed an “overweight” rating and set a $130.00 price target on shares of Monopar Therapeutics in a research report on Monday, August 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $121.36.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd acquired a new position in Monopar Therapeutics during the 4th quarter worth $86,000. Your Advocates Ltd. LLP acquired a new stake in shares of Monopar Therapeutics during the first quarter worth about $183,000. The Manufacturers Life Insurance Company bought a new position in Monopar Therapeutics in the first quarter valued at approximately $250,000. Sei Investments Co. boosted its stake in Monopar Therapeutics by 9.5% in the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after purchasing an additional 656 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of Monopar Therapeutics during the fourth quarter worth about $654,000. 1.83% of the stock is owned by institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. The company’s programs are designed to address significant limitations associated with existing cancer therapies, including treatment resistance and dose-limiting toxicity.

Monopar’s lead clinical program is camsirubicin, an investigational next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The drug is designed to retain the anticancer activity of anthracyclines while reducing the risk of cumulative heart damage associated with conventional doxorubicin.